Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of Its Entire DNA Solid Tumor Portfolio

Key Takeaways

• Tempus xT CDx now FDA‑cleared for tumor‑only testing
• Enables use without matched normal sample, expanding clinical applicability
• First lab with both tumor‑only and tumor‑normal CDx approvals
• Anticipated $200 average selling price reduction starting 2027
• Allows migration of entire solid‑tumor DNA portfolio under unified pricing

Pulse Analysis

The FDA’s tumor‑only clearance for Tempus’s xT CDx platform marks a pivotal regulatory milestone in oncology diagnostics. By eliminating the requirement for a matched normal specimen, the assay becomes more flexible for real‑world clinical settings where blood or saliva samples are unavailable. This broader applicability aligns with the industry’s push toward streamlined next‑generation sequencing workflows that can deliver comprehensive genomic insights from a single tumor biopsy.

From a business perspective, the new indication unlocks Tempus’s strategy to consolidate its solid‑tumor DNA offerings under a single Advanced Diagnostic Laboratory Test (ADLT) pricing structure. The company projects an average selling price advantage of roughly $200 per test beginning in 2027, a cost reduction that could improve reimbursement prospects and make high‑complexity testing more affordable for health systems. Clinicians gain a reliable, FDA‑approved companion diagnostic for a range of targeted therapies, including cetuximab and panitumumab, enhancing treatment decision‑making.

Market‑wise, Tempus’s dual‑approval status sets a competitive benchmark, pressuring rivals to seek similar regulatory pathways. As precision medicine continues to integrate AI‑driven data analytics, the ability to offer both tumor‑only and tumor‑normal profiling under one platform may attract larger oncology networks and boost test volumes. The move also signals to investors that Tempus is positioning itself for sustainable revenue growth through pricing efficiency and expanded market reach, reinforcing its role as a leading AI‑enabled diagnostics provider.